Scott Huennekens - Sep 1, 2023 Form 4 Insider Report for NUVASIVE INC (NUVA)

Role
Director
Signature
/s/ Nathaniel B. Sisitsky, Attorney-in-Fact for R Scott Huennekens
Stock symbol
NUVA
Transactions as of
Sep 1, 2023
Transactions value $
$0
Form type
4
Date filed
9/5/2023, 04:52 PM
Previous filing
Jun 15, 2023
Next filing
May 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NUVA Common Stock, par value $0.001 per share Disposed to Issuer -1.36K -100% 0 Sep 1, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NUVA Restricted Stock Unit Disposed to Issuer $0 -2.58K -100% $0.00* 0 Sep 1, 2023 Common Stock 2.58K Direct F2, F3
transaction NUVA Restricted Stock Unit Disposed to Issuer $0 -3.1K -100% $0.00* 0 Sep 1, 2023 Common Stock 3.1K Direct F2, F3
transaction NUVA Restricted Stock Unit Disposed to Issuer $0 -2.7K -100% $0.00* 0 Sep 1, 2023 Common Stock 2.7K Direct F2, F3
transaction NUVA Restricted Stock Unit Disposed to Issuer $0 -3.79K -100% $0.00* 0 Sep 1, 2023 Common Stock 3.79K Direct F2, F3
transaction NUVA Restricted Stock Unit Disposed to Issuer $0 -4.82K -100% $0.00* 0 Sep 1, 2023 Common Stock 4.82K Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Scott Huennekens is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares.
F2 Represented a contingent right to receive one share of the Issuer's common stock upon vesting.
F3 Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.